Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · IEX Real-Time Price · USD
0.790
-0.012 (-1.45%)
Jul 22, 2024, 9:54 AM EDT - Market open
Biodexa Pharmaceuticals Employees
Biodexa Pharmaceuticals had 21 employees as of December 31, 2023. The number of employees decreased by 6 or -22.22% compared to the previous year.
Employees
21
Change (1Y)
-6
Growth (1Y)
-22.22%
Revenue / Employee
$22,966
Profits / Employee
-$426,703
Market Cap
188.24K
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
China SXT Pharmaceuticals | 78 |
Bluejay Diagnostics | 10 |
Dermata Therapeutics | 8 |
GRI Bio | 4 |
Salarius Pharmaceuticals | 2 |
BDRX News
- 3 days ago - Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewsWire
- 10 days ago - Cancer-Focused Nano-Cap Biodexa Pharmaceuticals Stock Is Surging On Thursday - Here's Why - Benzinga
- 11 days ago - Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data - Accesswire
- 20 days ago - Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024 - GlobeNewsWire
- 4 weeks ago - Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP) - GlobeNewsWire
- 5 weeks ago - Results of Annual General Meeting - GlobeNewsWire
- 6 weeks ago - Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona - GlobeNewsWire
- 7 weeks ago - Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer - Accesswire